Peter Munk Cardiac Centre and Cardiovascular Biobank, Canada

Certification Status: Invite Member

Registration Status: Completed

Objective: The PMCC CV Biobank collects, catalogues, and stores human biospecimens and clinical data from research participants with cardiovascular diseases for the purpose of unifying research across the PMCC. It is uniquely positioned to offer researchers access to centralized high-quality samples to advance novel research for the understanding, discovery, prevention and ultimately the cure of various cardiac illness.

Registered Biobank Name	Peter Munk Cardiac Centre and Cardiovascular Biobank
Biobank Leader	Fraser Amos
Country	Canada
Email for biobank inquiries	fraser.amos@uhn.ca
Principal Investigator	Dr. Filio Billia, Dr. Richard Weisel
Website	https://www.uhn.ca/PMCC/Research/PMCC_cardiovascular_biobank
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).